| Similar Articles |
|---|
 |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals.   |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
January 4, 2005
W.D. Crotty |
A StemCell First News of an FDA application sends StemCells' stock soaring. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
Bio-IT World
August 2005
Maureen McDonough |
U.K. Framework Offers Stem Cells a Future The United Kingdom has managed to cut through the noise surrounding stem cell research, creating a regulatory framework that fosters an environment of international collaboration and excellent R&D programs. And they try to do it all in an ethical way. |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
Reason
July 2005
Ronald Bailey |
Censored Science Speaking out on stem cells: The Washington Post noted that even President Bush's handpicked NIH director, Elias Zerhouni, may not be on board with administration's stem cell policy. |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
Salon.com
December 29, 2000
Arthur Allen |
Will Thompson, Bush clash over human embryo research? The HHS nominee supports it, but right-to-lifers want it stopped.... |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
The Motley Fool
October 14, 2005
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future. Virxsys... Raven Biotechnologies... |
The Motley Fool
April 3, 2006
Seth Jayson |
No Stemming the Flow of Shares Another year, another large dollop of shares to water down the juice at StemCells. This company excels at burning money, as its cash flow statements show. Invest accordingly. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
The Motley Fool
November 14, 2008
Brian Orelli |
Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. |
The Motley Fool
August 10, 2011
Brandon Glenn |
Athersys More Threatened Than Most by Falling Share Price Recent market movements have been brutal for small biotech Athersys. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
Reason
October 2001
Ronald Bailey |
Blastocyst Brouhaha Which human cells count as people? |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
Bio-IT World
July 15, 2003
Kevin Davies |
Stem Cell Suicide The International Society for Stem Cell Research must engage in a political discourse to salvage the hope of embryonic stem cell research. |
Scientific American
January 17, 2007
Charles Q. Choi |
A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials. |
Bio-IT World
October 14, 2004 |
Stem Cells and the Ballot Box Science policy is seldom a pivotal factor in U.S. presidential elections, but this year might be an exception. |
BusinessWeek
January 23, 2006
Arlene Weintraub |
A "Body Blow" To Stem Cell Research Funding for stem cell research in the U.S. wasn't so hot even before the Korean scandal broke. |
BusinessWeek
July 26, 2004
Arlene Weintraub |
The Stem-Cell Flap: Simmer Down Advocates are overstating stem cells' near-term ability to treat grave illnesses. In doing so, they not only distort the science; the hopes they raise among many people who are sick today are also sure to be dashed. |
BusinessWeek
July 18, 2005
Moon Ihlwan |
Stem Cell Sleuth Seoul is funding Hwang Woo Suk in a bid to turn Korea into a global research hub for stem cell research. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
The Motley Fool
October 3, 2007
Brian Orelli |
Big Pharma Loves Your Liver Three big pharma companies, AstraZeneca, GlaxoSmithKline, and Roche, are funding a stem-cell consortium. Investors, take note. |
Inc.
February 2005
Patrick J. Sauer |
The State of Stem Cell Research Californians are hoping that stem cell research will do for them what the invention of the car did for Michigan. |
Chemistry World
April 6, 2009
Rebecca Trager |
US funding boost - a threat to EU science? These developments have raised some concern about the possibility of a 'brain drain' from Europe to the US, as these falling barriers have quickly made the region a more appealing destination for researchers. |
| AskMen.com |
Synthetic Sperm Created British scientists claimed Wednesday to have created human sperm from stem cells, but other experts questioned their data. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
Scientific American
December 2008
Tim Hornyak |
Turning Back the Cellular Clock: A Farewell to Embryonic Stem Cells? Shinya Yamanaka discovered how to revert adult cells to an embryonic state. These induced pluripotent stem cells might soon supplant their embryonic cousins in therapeutic promise |
Scientific American
July 2008
Sally Lehrman |
Dolly's Creator Moves Away from Cloning and Embryonic Stem Cells Like many stem cell pioneers, Ian Wilmut, the creator of Dolly the sheep, has jumped to an alternative approach. Is this the beginning of the end for embryonic cloning? |
Chemistry World
February 4, 2011
Harriet Brewerton |
Transplant tracking Magnetic nanoparticles could be used to track neural stem cells after a transplant in order to monitor how the cells heal spinal injuries, say UK scientists. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Europe approves stem cell therapy A stem cell treatment for severe cornea damage has been granted conditional approval by the European commission. |
Investment Advisor
May 2007 |
The U.S. Court of Appeals Decision A PDF of the U.S. Court of Appeals for the District of Columbia Circuit's ruling on the Financial Planning Association vs. The Securities and Exchange Commission. |
The Motley Fool
January 20, 2012
Dan Caplinger |
Can Geron Recover in 2012? Let's look at this year's prospects for this company. |
